<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38931452</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>14</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Novel Anti-Enterovirus A71 Compounds Discovered by Repositioning Antivirals from the Open-Source MMV Pandemic Response Box.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">785</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph17060785</ELocationID><Abstract><AbstractText>The open-source drug library, namely, MMV Pandemic Response Box, contains 153 antiviral agents, a chemically and pharmacologically diverse mixture of early-stage, emerging anti-infective scaffolds, and mature compounds currently undergoing clinical development. Hence, the Pandemic Response Box might contain compounds that bind and interfere with target molecules or cellular pathways that are conserved or shared among the closely related viruses with enterovirus A71 (EV-A71). This study aimed to screen antiviral agents included in the Pandemic Response Box for repurposing to anti-EV-A71 activity and investigate the inhibitory effects of the compounds on viral replication. The compounds' cytotoxicity and ability to rescue infected cells were determined by % cell survival using an SRB assay. The hit compounds were verified for anti-EV-A71 activity by virus reduction assays for viral RNA copy numbers, viral protein synthesis, and mature particle production using qRT-PCR, Western blot analysis, and CCID<sub>50</sub> assay, respectively. It was found that some of the hit compounds could reduce EV-A71 genome replication and protein synthesis. D-D7 (2-pyridone-containing human rhinovirus 3C protease inhibitor) exhibited the highest anti-EV-A71 activity. Even though D-D7 has been originally indicated as a polyprotein processing inhibitor of human rhinovirus 3C protease, it could be repurposed as an anti-EV-A71 agent.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lochaiyakun</LastName><ForeName>Nattinee</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumthani 12120, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srimanote</LastName><ForeName>Potjanee</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumthani 12120, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thammasat University Research Unit in Molecular Pathogenesis and Immunology of Infectious Diseases, Thammasat University, Pathumthani 12120, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khantisitthiporn</LastName><ForeName>Onruedee</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Thammasat University Research Unit in Molecular Pathogenesis and Immunology of Infectious Diseases, Thammasat University, Pathumthani 12120, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumthani 12120, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thanongsaksrikul</LastName><ForeName>Jeeraphong</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-7238-9591</Identifier><AffiliationInfo><Affiliation>Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumthani 12120, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Thammasat University Research Unit in Molecular Pathogenesis and Immunology of Infectious Diseases, Thammasat University, Pathumthani 12120, Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>180208</GrantID><Agency>the Thailand Science Research and Innovation Fundamental Fund fiscal year 2023</Agency><Country /></Grant><Grant><GrantID>2567</GrantID><Agency>the Thammasat University Research Unit in Molecular Pathogenesis and Immunology of Infec-tious Disease</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antivirus drugs</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">enterovirus A71</Keyword><Keyword MajorTopicYN="N">hand-foot-mouth disease</Keyword><Keyword MajorTopicYN="N">repurposed drugs</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>27</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38931452</ArticleId><ArticleId IdType="pmc">PMC11206571</ArticleId><ArticleId IdType="doi">10.3390/ph17060785</ArticleId><ArticleId IdType="pii">ph17060785</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chang L.Y., Lin H.Y., Gau S.S., Lu C.Y., Hsia S.H., Huang Y.C., Huang L.M., Lin T.Y. Enterovirus A71 Neurologic Complications and Long-term Sequelae. J. Biomed. Sci. 2019;26:57. doi: 10.1186/s12929-019-0552-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0552-7</ArticleId><ArticleId IdType="pmc">PMC6688366</ArticleId><ArticleId IdType="pubmed">31395054</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh W.M., Badaruddin H., La H., Chen M.I., Cook A.R. Severity and Burden of Hand, Foot and Mouth Disease in Asia: A Modelling Study. BMJ Glob. Health. 2018;3:e000442. doi: 10.1136/bmjgh-2017-000442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2017-000442</ArticleId><ArticleId IdType="pmc">PMC5859810</ArticleId><ArticleId IdType="pubmed">29564154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong K.C., Wong K.T. Understanding Enterovirus 71 Neuropathogenesis and Its Impact on Other Neurotropic Enteroviruses. Brain Pathol. 2015;25:614–624. doi: 10.1111/bpa.12279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12279</ArticleId><ArticleId IdType="pmc">PMC8029433</ArticleId><ArticleId IdType="pubmed">26276025</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, Epidemiology, Pathogenesis, and Control of Enterovirus 71. Lancet Infect. Dis. 2010;10:778–790. doi: 10.1016/S1473-3099(10)70194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.D., Li P.Q., Huang Y.G., Li W., Ma L.Z., Wu L., Wang N., Lu J.M., Chen W.Q., Liu G.M., et al. Factors Associated with Fatal Outcome of Children with Enterovirus A71 Infection: A Case Series. Epidemiol. Infect. 2018;146:788–798. doi: 10.1017/S0950268818000468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268818000468</ArticleId><ArticleId IdType="pmc">PMC9134374</ArticleId><ArticleId IdType="pubmed">29526169</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J., Wanlapakorn N., Vongpunsawad S., Poovorawan Y. The History of Enterovirus A71 Outbreaks and Molecular Epidemiology in The Asia-Pacific Region. J. Biomed. Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Jit M., Wu J.T., Yang J., Leung K., Liao Q., Yu H. Economic Costs and Health-related Quality of Life for Hand, Foot and Mouth Disease (HFMD) Patients in China. PLoS ONE. 2017;2:e0184266. doi: 10.1371/journal.pone.0184266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0184266</ArticleId><ArticleId IdType="pmc">PMC5608208</ArticleId><ArticleId IdType="pubmed">28934232</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Liu Y., Liu F., Ren M., Nie T., Cui J., Chang Z., Li Z. Basic Reproduction Number of Enterovirus 71 and Coxsackievirus A16 and A6: Evidence From Outbreaks of Hand, Foot, and Mouth Disease in China between 2011 and 2018. Clin. Infect. Dis. 2021;73:e2552–e2559. doi: 10.1093/cid/ciaa1853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1853</ArticleId><ArticleId IdType="pubmed">33320199</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R., Liu L., Mo Z., Wang X., Xia J., Liang Z., Zhang Y., Li Y., Mao Q., Wang J., et al. An Inactivated Enterovirus 71 Vaccine in Healthy Children. New Engl. J. Med. 2014;370:829–837. doi: 10.1056/NEJMoa1303224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei M., Meng F., Wang S., Li J., Zhang Y., Mao Q., Hu Y., Liu P., Shi N., Tao H., et al. 2-Year Efficacy, Immunogenicity, and Safety of Vigoo Enterovirus 71 Vaccine in Healthy Chinese Children: A Randomized Open-Label Study. J. Infect. Dis. 2017;215:56–63. doi: 10.1093/infdis/jiw502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw502</ArticleId><ArticleId IdType="pubmed">28077584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, Safety, and Immunogenicity of An Enterovirus 71 Vaccine in China. New Engl. J. Med. 2014;370:818–828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 Antivirals: Past, Present, and Future. Acta Pharm. Sin. B. 2022;12:1542–1566. doi: 10.1016/j.apsb.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Pang Z., Fan H., Tong Y. Advances in Anti-EV-A71 Drug Development Research. J. Adv. Res. 2024;56:137–156. doi: 10.1016/j.jare.2023.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2023.03.007</ArticleId><ArticleId IdType="pmc">PMC10834817</ArticleId><ArticleId IdType="pubmed">37001813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercorelli B., Palù G., Loregian A. Drug Repurposing for Viral Infectious Diseases: How Far Are We? Trends Microbiol. 2018;26:865–876. doi: 10.1016/j.tim.2018.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2018.04.004</ArticleId><ArticleId IdType="pmc">PMC7126639</ArticleId><ArticleId IdType="pubmed">29759926</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Peng T. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery. Front. Pharmacol. 2021;12:660710. doi: 10.3389/fphar.2021.660710.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.660710</ArticleId><ArticleId IdType="pmc">PMC8129523</ArticleId><ArticleId IdType="pubmed">34017257</ArticleId></ArticleIdList></Reference><Reference><Citation>Samby K., Besson D., Dutta A., Patra B., Doy A., Glossop P., Mills J., Whitlock G., van Huijsduijnen R.H., Monaco A., et al. The Pandemic Response Box—Accelerating Drug Discovery Efforts after Disease Outbreaks. ACS Infect. Dis. 2022;8:713–720. doi: 10.1021/acsinfecdis.1c00527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.1c00527</ArticleId><ArticleId IdType="pmc">PMC9003238</ArticleId><ArticleId IdType="pubmed">35286809</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi R., Zhou M., Shek R., Wilson J.W., Tillery L., Craig J.K., Salukhe I.A., Hickson S.E., Kumar N., James R.M., et al. High-throughput Screening of the ReFRAME, Pandemic Box, and COVID Box Drug Repurposing Libraries against SARS-CoV-2 Nsp15 Endoribonuclease to Identify Small-molecule Inhibitors of Viral Activity. PLoS ONE. 2021;16:e0250019. doi: 10.1371/journal.pone.0250019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0250019</ArticleId><ArticleId IdType="pmc">PMC8062000</ArticleId><ArticleId IdType="pubmed">33886614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes R.S., de Godoy A.S., Santos I.A., Noske G.D., de Oliveira K.I.Z., Gawriljuk V.O., Gomes Jardim A.C., Oliva G. Discovery of an Imidazonaphthyridine and a Riminophenazine as Potent Anti-Zika Virus Agents Through a Replicon-based High-throughput Screening. Virus Res. 2021;299:198388. doi: 10.1016/j.virusres.2021.198388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198388</ArticleId><ArticleId IdType="pubmed">33887282</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.N., Song Z.G., Jiang T., Shi B.S., Hu Y.W., Yuan Z.H. Rupintrivir is a Promising Candidate for Treating Severe Cases of Enterovirus-71 Infection. World J. Gastroenterol. 2010;16:201–209. doi: 10.3748/wjg.v16.i2.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v16.i2.201</ArticleId><ArticleId IdType="pmc">PMC2806558</ArticleId><ArticleId IdType="pubmed">20066739</ArticleId></ArticleIdList></Reference><Reference><Citation>Janissen R., Woodman A., Shengjuler D., Vallet T., Lee K.M., Kuijpers L., Moustafa I.M., Fitzgerald F., Huang P.N., Perkins A.L., et al. Induced Intra- and Intermolecular Template Switching as a Therapeutic Mechanism against RNA Viruses. Mol. Cell. 2021;81:4467–4480.e7. doi: 10.1016/j.molcel.2021.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2021.10.003</ArticleId><ArticleId IdType="pmc">PMC8628313</ArticleId><ArticleId IdType="pubmed">34687604</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandemic Response Box Supporting Information.  [(accessed on 26 May 2024)].  Available online:  https://www.mmv.org/mmv-open/pandemic-response-box/pandemic-response-box-supporting-information.</Citation></Reference><Reference><Citation>2D Structure Image of CID 6478675 (2-Pyridone-Containing Peptidomimetics)  [(accessed on 26 May 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/6478675.</Citation></Reference><Reference><Citation>2D Structure Image of CID 71481097 (Selinexor)  [(accessed on 26 May 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/71481097.</Citation></Reference><Reference><Citation>2D Structure Image of CID 5271819 (T-1106)  [(accessed on 26 May 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/5271819.</Citation></Reference><Reference><Citation>2D Structure Image of CID 2782 (Clemizole)  [(accessed on 26 May 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/2782.</Citation></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Johnson T.O., Hua Y., Luu H.T., Sakata S.K., Brown E.L., Maldonado F.C., Tuntland T., et al. Structure-based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-containing Peptidomimetics. J. Med. Chem. 2003;46:4572–4585. doi: 10.1021/jm030166l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm030166l</ArticleId><ArticleId IdType="pubmed">14521419</ArticleId></ArticleIdList></Reference><Reference><Citation>Podar K., Shah J., Chari A., Richardson P.G., Jagannath S. Selinexor for the Treatment of Multiple Myeloma. Expert Opin. Pharmacother. 2020;21:399–408. doi: 10.1080/14656566.2019.1707184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2019.1707184</ArticleId><ArticleId IdType="pubmed">31957504</ArticleId></ArticleIdList></Reference><Reference><Citation>Einav S., Sobol H.D., Gehrig E., Glenn J.S. The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors. J. Infect. Dis. 2010;202:65–74. doi: 10.1086/653080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/653080</ArticleId><ArticleId IdType="pmc">PMC3008401</ArticleId><ArticleId IdType="pubmed">20486856</ArticleId></ArticleIdList></Reference><Reference><Citation>2D Structure Image of CID 24780598 (Danirixin)  [(accessed on 26 May 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/24780598.</Citation></Reference><Reference><Citation>2D Structure Image of CID 1455 (Pocapavir)  [(accessed on 26 May 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/1455.</Citation></Reference><Reference><Citation>2D Structure Image of CID 65015 (Plerixafor)  [(accessed on 26 May 2024)]; Available online:  https://pubchem.ncbi.nlm.nih.gov/compound/65015.</Citation></Reference><Reference><Citation>Madan A., Chen S., Yates P., Washburn M.L., Roberts G., Peat A.J., Tao Y., Parry M.F., Barnum O., McClain M.T., et al. Co-administered With Standard-of-Care Antiviral (Oseltamivir): A Phase 2b, Global, Randomized Study of Adults Hospitalized with Influenza. Open Forum Infect. Dis. 2019;6:ofz163. doi: 10.1093/ofid/ofz163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz163</ArticleId><ArticleId IdType="pmc">PMC6483311</ArticleId><ArticleId IdType="pubmed">31041358</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanko K., Sun L., Froeyen M., Leyssen P., Delang L., Mirabelli C., Neyts J. Comparative Analysis of the Molecular Mechanism of Resistance to Vapendavir across a Panel of Picornavirus Species. Antivir. Res. 2021;195:105177. doi: 10.1016/j.antiviral.2021.105177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2021.105177</ArticleId><ArticleId IdType="pmc">PMC8593553</ArticleId><ArticleId IdType="pubmed">34517053</ArticleId></ArticleIdList></Reference><Reference><Citation>DiPersio J.F., Uy G.L., Yasothan U., Kirkpatrick P. Plerixafor. Nat. Rev. Drug Discov. 2009;8:105–107. doi: 10.1038/nrd2819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2819</ArticleId><ArticleId IdType="pubmed">19180104</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . Polio Laboratory Manual. 4th ed. World Health Organization; Geneva, Switzerland: 2004.  [(accessed on 26 May 2024)].  Available online:  http://apps.who.int/iris/bitstream/10665/68762/1/WHO_IVB_04.10.pdf.</Citation></Reference><Reference><Citation>Dragovich P.S., Prins T.J., Zhou R., Brown E.L., Maldonado F.C., Fuhrman S.A., Zalman L.S., Tuntland T., Lee C.A., Patick A.K., et al. Structure-based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structure-activity Studies of Orally Bioavailable, 2-Pyridone-containing Peptidomimetics. J. Med. Chem. 2002;45:1607–1623. doi: 10.1021/jm010469k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm010469k</ArticleId><ArticleId IdType="pubmed">11931615</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Wang J., Fan T., Qin B., Guo L., Lei X., Wang J., Wang M., Jin Q. Crystal Structure of Human Enterovirus 71 3C Protease. J. Mol. Biol. 2011;408:449–461. doi: 10.1016/j.jmb.2011.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.03.007</ArticleId><ArticleId IdType="pmc">PMC7094522</ArticleId><ArticleId IdType="pubmed">21396941</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Sun Z., Liu X., Jin Q., He B., Wang J. Cleavage of The Adaptor Protein TRIF by Enterovirus 71 3C Inhibits Antiviral Responses Mediated by Toll-like Receptor 3. J. Virol. 2011;85:8811–8818. doi: 10.1128/JVI.00447-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00447-11</ArticleId><ArticleId IdType="pmc">PMC3165803</ArticleId><ArticleId IdType="pubmed">21697485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kashyap T., Murray J., Walker C.J., Chang H., Tamir S., Hou B., Shacham S., Kauffman M.G., Tripp R.A., Landesman Y. Selinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces SARS-CoV-2 Infection and Protects The Respiratory System In Vivo. Antivir. Res. 2021;192:105115. doi: 10.1016/j.antiviral.2021.105115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2021.105115</ArticleId><ArticleId IdType="pmc">PMC8213878</ArticleId><ArticleId IdType="pubmed">34157321</ArticleId></ArticleIdList></Reference><Reference><Citation>Suanpan K., Srimanote P., Tongtawe P., Khantisitthiporn O., Supasorn O., Rattanakomol P., Thanongsaksrikul J. Transcriptome of Human Neuroblastoma SH-SY5Y Cells in Response to 2B Protein of Enterovirus-A71. Sci. Rep. 2022;12:1765. doi: 10.1038/s41598-022-05904-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-05904-6</ArticleId><ArticleId IdType="pmc">PMC8810792</ArticleId><ArticleId IdType="pubmed">35110649</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia X., Ganter B., Meier C. Improving Properties of The Nucleobase Analogs T-705/T-1105 As Potential Antiviral. Annu. Rep. Med. Chem. 2021;57:1–47. doi: 10.1016/bs.armc.2021.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.armc.2021.08.002</ArticleId><ArticleId IdType="pmc">PMC8553380</ArticleId><ArticleId IdType="pubmed">34728864</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Torres S., Myers A.L., Klatte J.M., Rhoden E.E., Oberste M.S., Collett M.S., McCulloh R.J. First Use of Investigational Antiviral Drug Pocapavir (v-073) for Treating Neonatal Enteroviral Sepsis. Pediatr. Infect. Dis. J. 2015;34:52–54. doi: 10.1097/INF.0000000000000497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000497</ArticleId><ArticleId IdType="pubmed">25229269</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein S., Thakkar R., Fong K.T., Ng J., Bearden D.R., Mishra N., Thakur K.T., Riley C.S. Compassionate-use Pocapavir and Immunoglobulin Therapy for Treatment of Rituximab-associated Enterovirus Meningoencephalitis. J. Neurovirol. 2022;28:329–334. doi: 10.1007/s13365-021-01038-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-01038-z</ArticleId><ArticleId IdType="pubmed">34981437</ArticleId></ArticleIdList></Reference><Reference><Citation>Copelyn J., Hincks J.R., Wilmshurst J.M., Petersen W., Howard W., Jallow S., Moonsamy S., Seakamela L., Suchard M., Collett M.S., et al. Clearance of Immunodeficiency-associated Vaccine-derived Poliovirus Infection with Pocapavir. Pediatr. Infect. Dis. J. 2020;39:435–437. doi: 10.1097/INF.0000000000002584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000002584</ArticleId><ArticleId IdType="pubmed">32150007</ArticleId></ArticleIdList></Reference><Reference><Citation>Catching A., Te Yeh M., Bianco S., Capponi S., Andino R. A Tradeoff Between Enterovirus A71 Particle Stability and Cell Entry. Nat. Commun. 2023;14:7450. doi: 10.1038/s41467-023-43029-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43029-0</ArticleId><ArticleId IdType="pmc">PMC10656440</ArticleId><ArticleId IdType="pubmed">37978288</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.C., Chang C.L., Wang P.S., Tsai Y., Liu H.S. Enterovirus 71-induced Autophagy Detected In Vitro and In Vivo Promotes Viral Replication. J. Med. Virol. 2009;81:1241–1252. doi: 10.1002/jmv.21502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.21502</ArticleId><ArticleId IdType="pmc">PMC7166624</ArticleId><ArticleId IdType="pubmed">19475621</ArticleId></ArticleIdList></Reference><Reference><Citation>Caspar B., Cocchiara P., Melet A., Van Emelen K., Van der Aa A., Milligan G., Herbeuval J.P. CXCR4 as a Novel Target in Immunology: Moving Away from Typical Antagonists. Future Drug Discov. 2022;4:FDD77. doi: 10.4155/fdd-2022-0007.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/fdd-2022-0007</ArticleId><ArticleId IdType="pmc">PMC9298491</ArticleId><ArticleId IdType="pubmed">35875591</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., Bauer M., Press A.T. The Immunological Function of CXCR2 in The Liver During Sepsis. J. Inflamm. 2022;19:23. doi: 10.1186/s12950-022-00321-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-022-00321-y</ArticleId><ArticleId IdType="pmc">PMC9714102</ArticleId><ArticleId IdType="pubmed">36451225</ArticleId></ArticleIdList></Reference><Reference><Citation>Kremer K.N., Peterson K.L., Schneider P.A., Meng X.W., Dai H., Hess A.D., Smith B.D., Rodriguez-Ramirez C., Karp J.E., Kaufmann S.H., et al. CXCR4 Chemokine Receptor Signaling Induces Apoptosis in Acute Myeloid Leukemia Cells via Regulation of The Bcl-2 Family Members Bcl-XL, Noxa, and Bak. J. Biol. Chem. 2013;288:22899–22914. doi: 10.1074/jbc.M113.449926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.449926</ArticleId><ArticleId IdType="pmc">PMC3743469</ArticleId><ArticleId IdType="pubmed">23798675</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Li F., Pan Z., Wu Z., Wang Y., Cui Y. Activation of PI3K/Akt Pathway Limits JNK-mediated Apoptosis during EV71 Infection. Virus Res. 2014;192:74–84. doi: 10.1016/j.virusres.2014.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2014.07.026</ArticleId><ArticleId IdType="pubmed">25116390</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanongsaksrikul J., Srimanote P., Tongtawe P., Glab-Ampai K., Malik A.A., Supasorn O., Chiawwit P., Poovorawan Y., Chaicumpa W. Identification and Production of Mouse ScFv to Specific Epitope of Enterovirus-71 Virion Protein-2 (VP2) Arch. Virol. 2018;163:1141–1152. doi: 10.1007/s00705-018-3731-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-018-3731-z</ArticleId><ArticleId IdType="pubmed">29356992</ArticleId></ArticleIdList></Reference><Reference><Citation>Vichai V., Kirtikara K. Sulforhodamine B Colorimetric Assay for Cytotoxicity Screening. Nat. Protoc. 2006;1:1112–1116. doi: 10.1038/nprot.2006.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.179</ArticleId><ArticleId IdType="pubmed">17406391</ArticleId></ArticleIdList></Reference><Reference><Citation>Rattanakomol P., Srimanote P., Tongtawe P., Khantisitthiporn O., Supasorn O., Thanongsaksrikul J. Host Neuronal PRSS3 Interacts with Enterovirus A71 3A Protein and Its Role in Viral Replication. Sci. Rep. 2022;12:12846. doi: 10.1038/s41598-022-17272-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17272-2</ArticleId><ArticleId IdType="pmc">PMC9328647</ArticleId><ArticleId IdType="pubmed">35896602</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>